Effects of chitosan and oligochitosans on the phosphatidylinositol 3-kinase-AKT pathway in cancer therapy

Amirani, E. and Hallajzadeh, J. and Asemi, Z. and Mansournia, M.A. and Yousefi, B. (2020) Effects of chitosan and oligochitosans on the phosphatidylinositol 3-kinase-AKT pathway in cancer therapy. International Journal of Biological Macromolecules, 164. pp. 456-467.

Full text not available from this repository.
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....
DOI: UNSPECIFIED

Abstract

Phosphatidylinositol 3-kinase (PI3K)-AKT pathway is one of the most important kinase signaling networks in the context of cancer development and treatment. Aberrant activation of AKT, the central mediator of this pathway, has been implicated in numerous malignancies including endometrial, hepatocellular, breast, colorectal, prostate, and, cervical cancer. Thus regulation and blockage of this kinase and its key target nodes is an attractive approach in cancer therapy and diverse efforts have been done to achieve this aim. Chitosan is a carbohydrate with multiple interesting applications in cancer diagnosis and treatment strategies. This bioactive polymer and its derivative oligomers commonly used in drug/DNA delivery methods due to their functional properties which improve efficiency of delivery systems. Further, these compounds exert anti-tumor roles through the stimulation of apoptosis, immune enhancing potency, anti-oxidative features and anti-angiogenic roles. Due to the importance of PI3K-AKT signaling in cancer targeting and treatment resistance, this review discusses the involvement of chitosan, oligochitosaccharides and carriers based on these chemicals in the regulation of this pathway in different tumors. © 2020 Elsevier B.V.

Item Type: Article
Additional Information: cited By 0
Uncontrolled Keywords: AKT1 protein; antineoplastic agent; ATM protein; beta catenin; chitooligosaccharide; chitosan; chitosan nanoparticle; cycline; glycogen synthase kinase 3beta; immunoglobulin enhancer binding protein; mammalian target of rapamycin; mitogen activated protein kinase; mitogen activated protein kinase 1; mitogen activated protein kinase 3; mitogen activated protein kinase p38; nerve cell adhesion molecule; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase; oligochitosan derivative; phosphatidylinositol 3 kinase; protein bcl 2; protein c fos; protein kinase B; protein kinase B beta; protein p21; protein p53; protein serine threonine kinase; stress activated protein kinase 1; transcription factor EZH2; transcription factor RelA; unclassified drug; unindexed drug, angiogenesis; antiangiogenic activity; antiinflammatory activity; antimicrobial activity; antineoplastic activity; antioxidant activity; antiproliferative activity; apoptosis; biodegradation; breast cancer; cancer gene therapy; cancer inhibition; cancer therapy; cell growth; cell metabolism; cell proliferation; cell survival; colon cancer; colorectal cancer; drug delivery system; Ehrlich ascites tumor; epithelial mesenchymal transition; human; intestine mucosa permeability; kidney sarcoma; leukemia; liver cell carcinoma; lung cancer; lung carcinoma; melanoma; metastasis inhibition; mucoadhesion; non small cell lung cancer; nonhuman; osteosarcoma; pancreas cancer; Pi3K/Akt signaling; protein synthesis; Review; solubility; stomach cancer; uterine cervix cancer
Subjects: Biochemistry, Genetics and Molecular Biology
Pharmacology, Toxicology and Pharmaceutics
Divisions: Faculty of Medicine > Basic Sciences > Department of Biochemistry
Depositing User: ART . editor
Date Deposited: 09 Jan 2021 11:35
Last Modified: 09 Jan 2021 11:35
URI: http://eprints.kaums.ac.ir/id/eprint/5290

Actions (login required)

View Item View Item